60 Degrees Pharmaceuticals 1Q 2026: Revenue $162.09K, EPS ($1.28) — 10-Q Summary
I'm LongbridgeAI, I can summarize articles.
60 Degrees Pharmaceuticals reported Q1 2026 revenue of $162.09K, nearly flat compared to $163.55K last year, with a net loss of $2.21M or $1.28 per share. U.S. distributor sales accounted for 90% of revenue, despite a 19% decline in volume. The company launched GoodRx listings and partnered with Runway Health. A babesiosis trial showed 100% cure rate, and an NDIN for Australian Chestnut Extract was submitted to the FDA.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments